Abstract: Disclosed are medicaments, pharmaceutical compositions, pharmaceutical kits, and methods based on combinations comprising, separately or together: (a) a CYP3A4 inhibitor; and (b) a HCV protease inhibitor; for concurrent or consecutive administration in treating a human subject infected with HCV.

Abstract: An executable is downloaded to an audio output device over a communications link. The executable may configure the audio output device to decode audio encoded in a specified format. The executable may also or alternatively include other audio processing software. The audio may include voice and/or audio playback, e.g., music playback. The ability to download an audio executable allows dynamic provisioning of various decoding and/or audio process capabilities to an audio output device. This may eliminate the need to transcode digitized audio for playback at the audio output device, and may also allow the audio output device to decode multiple audio formats without having multiple audio decoders permanently residing within the audio output device.

Abstract: This disclosure describes techniques that make use of a plurality of hardware elements that operate simultaneously to service synthesis parameters generated from one or more audio files, such as musical instrument digital interface (MIDI) files. In one example, a method comprises storing audio synthesis parameters generated for one or more audio files of an audio frame, processing a first audio synthesis parameter using a first audio processing element of a hardware unit to generate first audio information, processing a second audio synthesis parameter using a second audio processing element of the hardware unit to generate second audio information, and generating audio samples for the audio frame based at least in part on a combination of the first and second audio information.

Abstract: This disclosure describes techniques for processing audio files that comply with the musical instrument digital interface (MIDI) format. In particular, various tasks associated with MIDI file processing are delegated between software operating on a general purpose processor, firmware associated with a digital signal processor (DSP), and dedicated hardware that is specifically designed for MIDI file processing. Alternatively, a multi-threaded DSP may be used instead of a general purpose processor and the DSP. In one aspect, this disclosure provides a method comprising parsing MIDI files and scheduling MIDI events associated with the MIDI files using a first process, processing the MIDI events using a second process to generate MIDI synthesis parameters, and generating audio samples using a hardware unit based on the synthesis parameters.

Abstract: Embodiments of methods, apparatuses, devices and systems associated with compression and decompression of digital signals are disclosed.

Abstract: Power savings in a mobile device is accomplished by generating audio samples by decoding a bitstream with a decoding system within the mobile device. The generated audio samples are transferred into at least one memory bank in a set of memory banks in a power saver block within the mobile device. Parts of the decoding system not involved in the storing of the generated audio samples are switched off after batch decoding a bitstream associated with multiple audio frames. The bitstream includes bits less than that found in one audio file. At least one of the memory banks in the set of memory banks is power collapsible. The fetching of the decoded by the decoding system can be synchronized with a paging channel of a modem in the mobile device. The transferred audio samples is a lossless compression and may occur after a re-encoding.

Abstract: A method of treating and/or preventing allergic and inflammatory conditions of the skin or upper and lower airway passages, e.g. seasonal allergic rhinitis, perennial allergic rhinitis, or chronic idopathic urticaria, in a human more 12 years old, by administering an amount of desloratadine, e.g. 2×2.5 mg or 5 mg/day for a time sufficient to produce a geometric mean steady state maximum plasma concentration of desloratadine in the range of about 2.90 ng/mL to about 4.54 ng/mL, or a arithmetic mean steady state maximum plasma concentration of desloratadine in the range of about 3.2 ng/mL to about 5.0 ng/mL is disclosed.

Abstract: A method of treating and/or preventing allergic and inflammatory conditions of the skin or upper and lower airway passages, e.g. seasonal allergic rhinitis, perennial allergic rhinitis, or chronic idopathic urticaria, in a human more 12 years old, by administering an amount of desloratadine, e.g. 2×2.5 mg or 5 mg/day for a time sufficient to produce a geometric mean steady state maximum plasma concentration of desloratadine in the range of about 2.90 ng/mL to about 4.54 ng/mL, or a arithmetic mean steady state maximum plasma concentration of desloratadine in the range of about 3.2 ng/mL to about 5.0 ng/mL is disclosed.

Abstract: The use of desloratadine for the preparation of a medicament for treating and/or preventing allergic and inflammatory conditions of the skin or upper and lower airway passages in a human while avoiding the food effect associated with non-sedating antihistamines, e.g., loratadine or fexofenadine is disclosed.

Abstract: A system and method for canceling an echo signal. An input waveform is provided to an acoustic processor, and a determination is made whether the input waveform includes information representative of an echo signal. If the input waveform includes information representative of an echo signal, an output waveform is formed by attenuating a residual waveform with the acoustic processor. The residual waveform is attenuated by an attenuation factor that gradually changes from an initial attenuation value to a final attenuation value during the attenuation step. A system and method for adjusting an acoustic signal from a muted state to an unmuted state by varying an attenuation factor applied to an acoustic signal by an acoustic processor. The acoustic signal is provided to an acoustic processor. An output waveform is formed from the acoustic processor by adjusting the attenuation factor from a muted state to a first attenuation value associated with the non-muted state.

Abstract: A system and method for canceling an echo signal. An input waveform is provided to an acoustic processor, and a determination is made whether the input waveform includes information representative of an echo signal. If the input waveform includes information representative of an echo signal, an output waveform is formed by attenuating a residual waveform with the acoustic processor. The residual waveform is attenuated by an attenuation factor that gradually changes from an initial attenuation value to a final attenuation value during the attenuation step.

Abstract: The use of desloratadine for the preparation of a medicament for treating and/or preventing an allergic and inflammatory condition of the skin or upper and lower airway passages in a pediatric patient and a pediatric pharmaceutical composition effective for such treating and/or preventing which comprises an effective amount of desloratadine and a pharmaceutically acceptable carrier are disclosed.

Abstract: A method of treating and/or preventing allergic and inflammatory conditions of the skin or upper and lower airway passages, e.g. seasonal allergic rhinitis, pernninal allergic rhinitis, or chronic idopathic urticaria, in a human more 12 years old, by administering an amount of desloratadine, e.g. 2×2.5 mg or 5 mg/day for a time sufficient to produce a geometric mean steady state maximum plasma concentration of desloratadine in the range of about 2.90 ng/mL to about 4.54 ng/mL, or a arithmetic mean steady state maximum plasma concentration of desloratadine in the range of about 3.2 ng/mL to about 5.0 ng/mL is disclosed.

Abstract: A method of therapeutically administering certain medicaments, for instance levo-deprenyl and/or levo-desmethyl deprenyl, in order to maximize the desired effects and minimize the unwanted metabolite effects on the human body, including the central nervous system, in order to maximize therapeutic effects, such as antianxiety, anticonvulsant, antidepression, antioxidant, anti-Parkinson's disease, anti-Alzheimer's disease, and hypnotic effects, and minimize unwanted side effects, such as ataxic, anxiety, and incoordination effects, of the medicament, for instance by intraoral administration and/or inhalation administration

Abstract: A method of therapeutically administering certain medicaments in order to maximize the desired effects and minimize the unwanted metabolite effects on the human body, including the central nervous system, in order to maximize therapeutic effects, such as anti-anxiety, anticonvulsant and hypnotic effects, and minimize unwanted side effects, such as ataxic and incoordination effects, of the medicament. Also, a method of inhalation administration or skin administration of certain medicaments in order to decrease metabolism of the medicaments to unwanted metabolites.

Abstract: A method of therapeutically administering certain medicaments in order to maximize the desired effects and minimize the unwanted metabolite effects on the human body, including the central nervous system, in order to maximize therapeutic effects, such as anti-anxiety, anticonvulsant and hypnotic effects, and minimize unwanted side effects, such as ataxic and incoordination effects, of the medicament. Also, a method of inhalation administration or skin administration of certain medicaments in order to decrease metabolism of the medicaments to unwanted metabolites.

Abstract: A method of therapeutically administering certain medicaments in order to maximize the desired effects and minimize the unwanted metabolite effects on the human body, including the central nervous system, in order to maximize therapeutic effects, such as anti-anxiety, anticonvulsant and hypnotic effects, and minimize unwanted side effects, such as ataxic and incoordination effects, of the drug. Also, a method of sublingual or buccal administration of certain medicaments in order to decrease metabolism of the medicaments to unwanted metabolites.

Abstract: A method of therapeutically administering certain BZ.sub.1 specific trifluorobenzodiazepines in order to maximize the BZ.sub.1 effects and minimize the BZ.sub.2 effects on the human central nervous system in order to maximize the anti-anxiety, anticonvulsant and hypnotic effects and minimize the ataxic and incoordination effects of the drug. Also, a method of sublingual administration of trifluorobenzodiazepines and certain other compounds, such as propoxyphene and nefazodone, in order to decrease unwanted metabolites.

Abstract: A method of therapeutically administering certain BZ.sub.1 specific trifluorobenzodiazepines in order to maximize the BZ.sub.1 effects and minimize the BZ.sub.2 effects on the human central nervous system in order to maximize the anti-anxiety, anticonvulsant and hypnotic effects and minimize the ataxic and incoordination effects of the drug. Also, a method of sublingual administration of trifluorobenzodiazepines and certain other compounds in order to decrease unwanted dealkylated metabolites.

Abstract: A method of therapeutically administering certain BZ.sub.1 specific trifluorobenzodiazepines in order to maximize the BZ.sub.1 effects and minimize the BZ.sub.2 effects on the human central nervous system in order to maximize the anti-anxiety, anticonvulsant and hypnotic effects and minimize the ataxic and incoordination effects of the drug.